How India Exports Combiflam to the World

As of March 2026, the FDA's Orange Book does not list any approved Abbreviated New Drug Applications (ANDAs) for Combiflam or its generic equivalents. This indicates that no manufacturers have received FDA approval to market this specific combination in the United States. Consequently, Combiflam is not authorized for sale in the U.S. market.

The absence of FDA approval suggests that Indian exporters have not pursued the regulatory pathway required for U.S. market entry, which involves submitting an ANDA demonstrating bioequivalence to a reference listed drug. Additionally, there are no import alerts related to Combiflam or its components from India, indicating no specific FDA concerns regarding this product.

In the European Union, the European Medicines Agency (EMA) oversees the approval of medicinal products. A similar combination of ibuprofen and paracetamol is available in some EU countries; however, specific marketing authorizations for Combiflam are not documented in EMA's centralized records. This suggests that Combiflam may not have sought or obtained centralized approval within the EU.

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) requires a marketing authorization for medicinal products. There is no public record indicating that Combiflam has obtained such authorization in the UK. Compliance with EU Good Manufacturing Practice (GMP) standards is mandatory for products marketed in these regions, ensuring quality and safety.

The World Health Organization (WHO) includes both ibuprofen and paracetamol individually in its Model List of Essential Medicines, recognizing their importance in healthcare. However, the combination of these two active ingredients, as found in Combiflam, is not listed in the current edition. This absence may influence procurement decisions by international health organizations.

Regarding pharmacopoeial standards, both ibuprofen and paracetamol are monographed in major compendia such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Compliance with these standards is essential for ensuring the quality and efficacy of pharmaceutical products.

In India, Combiflam is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, there is no specific ceiling price listed for the ibuprofen and paracetamol combination. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceutical products, ensuring compliance with export regulations.

The combination of ibuprofen and paracetamol is not under patent protection, allowing multiple manufacturers to produce and market generic versions. This lack of exclusivity has led to a competitive market landscape, both domestically and internationally.

In December 2025, the NPPA announced a revision of the ceiling prices for several essential medicines, although the ibuprofen and paracetamol combination was not included in this update. In January 2026, the CDSCO issued new guidelines for the export of pharmaceutical products, emphasizing the need for stringent quality checks and compliance with international standards. In February 2026, the WHO updated its Model List of Essential Medicines, maintaining the individual listings for ibuprofen and paracetamol but not including their combination.

These developments underscore the dynamic nature of the pharmaceutical regulatory environment and the importance of continuous monitoring to ensure compliance and market access.

Combiflam, a widely used analgesic and antipyretic, relies on active pharmaceutical ingredients (APIs) such as ibuprofen and paracetamol. India, a major producer of these APIs, often sources key starting materials (KSMs) from China, which controls approximately 70–80% of the global KSM supply. This dependency exposes the supply chain to risks associated with geopolitical tensions and trade disruptions.

Recent events have further highlighted these vulnerabilities. In March 2026, the closure of the Strait of Hormuz disrupted the supply of petrochemical feedstocks essential for API synthesis, leading to production cutbacks and increased costs. This situation underscores the fragility of pharmaceutical supply chains reliant on specific geographic regions for critical raw materials.

Our proprietary trade data indicates that the top five exporters of Combiflam from India account for 49.1% of total exports, with CAPSTONE EXPORT & IMPORT leading at a 21.0% share. This concentration suggests a moderate risk of supply disruption if any of these key suppliers face operational challenges.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic API production and reduce reliance on imports. However, the effectiveness of this initiative in diversifying the supplier base for Combiflam remains to be fully realized.

The closure of the Strait of Hormuz in March 2026 has had a profound impact on global supply chains, including the pharmaceutical sector. The strait's closure disrupted the supply of petrochemical feedstocks essential for API synthesis, leading to production cutbacks and increased costs.

Additionally, tensions in the Red Sea and the Strait of Hormuz have led to increased shipping costs and delays, further complicating the timely delivery of pharmaceutical products. The FDA has acknowledged these challenges and is actively working to monitor and mitigate potential drug shortages resulting from such geopolitical events.

• Diversify API and KSM Sources: Encourage the development of alternative suppliers in different geographic regions to reduce dependency on a single country or region.

• Enhance Domestic Production: Leverage government initiatives like the PLI scheme to strengthen domestic manufacturing capabilities for APIs and KSMs.

• Strengthen Supplier Relationships: Establish long-term contracts and collaborative partnerships with multiple suppliers to ensure a stable supply chain.

• Monitor Geopolitical Developments: Implement a robust system for tracking geopolitical events that could impact supply chains, allowing for proactive risk management.

• Invest in Supply Chain Resilience: Develop contingency plans, including alternative shipping routes and inventory buffers, to mitigate the impact of disruptions.

RISK_LEVEL: MEDIUM